Mink Therapeutics (INKT) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 18, 2025, to be held virtually, with voting on key proposals including director elections, an option exchange, and auditor ratification.

• Shareholders of record as of April 24, 2025, are eligible to vote; 3,966,392 shares outstanding.

• Proxy materials distributed via internet and mail, with multiple voting methods available.

Voting matters and shareholder proposals

• Proposal 1: Election of Jennifer Buell and Ulf Wiinberg as Class I directors for three-year terms expiring at the 2028 annual meeting.

• Proposal 2: Approval of a one-time option exchange for employees, directors, and consultants, replacing underwater options with new options at current market value.

• Proposal 3: Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board consists of seven members divided into three classes, with annual elections for one class.

• Three standing committees: Audit and Finance, Compensation, and Corporate Governance and Nominating; an Affiliate Transactions Committee addresses conflicts with Agenus.

• Majority of directors are independent; annual board and committee self-evaluations conducted.

• Code of Ethics and Securities Trading Policy updated in 2023; independent directors meet in executive session.